ArticleWorld journal of surgical oncology2026
Oncogenic SOX9-TRAIP signaling drives gastric cancer progression by mediating the degradation of the CPEB3-mTORC1 tumor suppressor axis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastric cancer (GC) is a leading cause of cancer mortality worldwide, driven by complex and heterogeneous molecular alterations. The ubiquitin-proteasome system, particularly E3 ubiquitin ligases, is frequently dysregulated in cancer, yet its key players in GC remain incompletely defined. This study aimed to identify novel oncogenic E3 ligases in GC and to elucidate their molecular mechanisms.
methodsWe performed a systematic multi-cohort transcriptomic analysis of public datasets (GEO, TCGA) to screen for and validate key E3 ubiquitin ligases. The oncogenic functions were validated using shRNA-mediated knockdown, overexpression, chromatin immunoprecipitation (ChIP), co-immunoprecipitation (Co-IP), ubiquitylation assays, luciferase reporter assays, and a series of cell-based functional assays (proliferation, colony formation, invasion), as well as a subcutaneous xenograft model in nude mice.
resultsWe identified TRAF-interacting protein (TRAIP), an E3 ubiquitin ligase, as a critically overexpressed gene in GC that strongly correlates with poor patient prognosis. We delineated a complete and linear signaling cascade, demonstrating that the oncogenic transcription factor SOX9 directly binds to the TRAIP promoter and drives its transcriptional upregulation. Mechanistically, TRAIP functions as the specific E3 ligase for the RNA-binding protein and tumor suppressor, CPEB3, mediating its poly-ubiquitylation and subsequent proteasomal degradation. This TRAIP-mediated destruction of CPEB3 relieves its translational repression of key oncogenic targets, leading to the hyperactivation of the mTORC1 signaling pathway. Functionally, TRAIP is indispensable for GC cell proliferation, invasion, and in vivo tumorigenicity. Epistatic rescue experiments revealed that the oncogenic effects of TRAIP are almost entirely dependent on its ability to degrade CPEB3.
conclusionOur findings define the SOX9-TRAIP-CPEB3-mTORC1 axis as a central, hierarchical signaling network driving GC progression. This work not only uncovers a novel oncogenic cascade but also provides a compelling mechanistic rationale for exploring the therapeutic potential of targeting this axis for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.